L S Gilchrist1, L Marais, L Tanner. 1. Physical Therapy Program, St. Catherine University, 601 25th Ave S, Minneapolis, MN, USA, lsgilchrist@stkate.edu.
Abstract
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment in children; however, measurement of CIPN has been hampered by limitations in available tools, which may impact prevalence estimates. The purpose of this study was to assess the relative ability of the Common Terminology Criteria (CTCAE) rating process to detect sensory and motor neuropathy as compared to administration of the pediatric modified Total Neuropathy Score (peds-mTNS). METHODS: The ped-mTNS was administered to 60 children/adolescents ages 5-18 undergoing treatment for acute lymphocytic leukemia, lymphoma, or non-CNS solid tumors. CTCAE v3.0 scores for the same time point were abstracted from the medical record by a separate trained rater. Comparisons were made between scores using descriptive statistics, correlations, and specificity and sensitivity calculations. RESULTS: The median ped-mTNS score was 9 (32 possible), while the median sensory and motor CTCAE ratings were 0 and 2, respectively (4 and 5 possible, respectively). There was no correlation between ped-mTNS and combined sensory and motor CTCAE scores. The only ped-mTNS item with significant correlation to CTCAE scoring was strength testing. Medical record abstraction of CTCAE scores failed to identify sensory neuropathy in 40 % and significant motor neuropathy (manual muscle test grade 3 or worse) in 15 % of subjects. CONCLUSIONS: Prospective measures of CIPN using the ped-mTNS identified a far greater proportion of subjects with peripheral neurotoxicity as compared to CTCAE v3.0 sensory and motor neuropathy ratings, and thus we recommend the use of a specific measure of CIPN such as the ped-mTNS.
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment in children; however, measurement of CIPN has been hampered by limitations in available tools, which may impact prevalence estimates. The purpose of this study was to assess the relative ability of the Common Terminology Criteria (CTCAE) rating process to detect sensory and motor neuropathy as compared to administration of the pediatric modified Total Neuropathy Score (peds-mTNS). METHODS: The ped-mTNS was administered to 60 children/adolescents ages 5-18 undergoing treatment for acute lymphocytic leukemia, lymphoma, or non-CNS solid tumors. CTCAE v3.0 scores for the same time point were abstracted from the medical record by a separate trained rater. Comparisons were made between scores using descriptive statistics, correlations, and specificity and sensitivity calculations. RESULTS: The median ped-mTNS score was 9 (32 possible), while the median sensory and motor CTCAE ratings were 0 and 2, respectively (4 and 5 possible, respectively). There was no correlation between ped-mTNS and combined sensory and motor CTCAE scores. The only ped-mTNS item with significant correlation to CTCAE scoring was strength testing. Medical record abstraction of CTCAE scores failed to identify sensory neuropathy in 40 % and significant motor neuropathy (manual muscle test grade 3 or worse) in 15 % of subjects. CONCLUSIONS: Prospective measures of CIPN using the ped-mTNS identified a far greater proportion of subjects with peripheral neurotoxicity as compared to CTCAE v3.0 sensory and motor neuropathy ratings, and thus we recommend the use of a specific measure of CIPN such as the ped-mTNS.
Authors: C C P Verstappen; S Koeppen; J J Heimans; P C Huijgens; M E Scheulen; D Strumberg; B Kiburg; T J Postma Journal: Neurology Date: 2005-03-22 Impact factor: 9.910
Authors: Kirsten K Ness; Melissa M Hudson; Ching-Hon Pui; Daniel M Green; Kevin R Krull; Tseng T Huang; Leslie L Robison; E Brannon Morris Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Kirsten K Ness; Kendra E Jones; Webb A Smith; Sheri L Spunt; Carmen L Wilson; Gregory T Armstrong; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: Arch Phys Med Rehabil Date: 2013-03-26 Impact factor: 3.966
Authors: Michael D Stubblefield; Harold J Burstein; Allen W Burton; Christian M Custodio; Gary E Deng; Maria Ho; Larry Junck; G Stephen Morris; Judith A Paice; Sudhakar Tummala; Jamie H Von Roenn Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Ellen M Lavoie Smith; Clare Kuisell; Grace A Kanzawa-Lee; Celia M Bridges; Paola Alberti; Guido Cavaletti; Rima Saad; Susanna Park Journal: Lancet Haematol Date: 2020-05 Impact factor: 18.959
Authors: Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness Journal: Lancet Child Adolesc Health Date: 2018-09-01
Authors: Ellen M Lavoie Smith; Lang Li; ChienWei Chiang; Karin Thomas; Raymond J Hutchinson; Elizabeth M Wells; Richard H Ho; Jodi Skiles; Arindom Chakraborty; Celia M Bridges; Jamie Renbarger Journal: J Peripher Nerv Syst Date: 2015-03 Impact factor: 3.494
Authors: Stephen Sands; Elena J Ladas; Kara M Kelly; Michael Weiner; Meiko Lin; Deborah Hughes Ndao; Amie Dave; Linda T Vahdat; Julia Glade Bender Journal: Support Care Cancer Date: 2016-11-09 Impact factor: 3.603
Authors: Samah Hayek; Tara M Brinkman; Juan C Plana; Vijaya M Joshi; Russell V Leupker; Jean B Durand; Daniel M Green; Robyn E Partin; Aimee K Santucci; Rebecca M Howell; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kirsten K Ness Journal: JAMA Oncol Date: 2020-08-01 Impact factor: 31.777
Authors: Donna L Johnston; Lillian Sung; Daniel Stark; A Lindsay Frazier; Abby R Rosenberg Journal: Support Care Cancer Date: 2016-04-01 Impact factor: 3.603